Share Price and Basic Stock Data
Last Updated: January 31, 2026, 8:18 pm
| PEG Ratio | -101.05 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarti Drugs Limited operates within the pharmaceuticals sector, with a current market capitalization of ₹3,409 Cr. As of March 2023, the company’s reported sales stood at ₹2,498 Cr, representing a growth trajectory from ₹2,251 Cr in March 2022. However, the latest reported TTM sales of ₹2,237 Cr indicate a slight contraction compared to the previous fiscal year. Quarterly sales figures show fluctuations; for instance, sales peaked at ₹696 Cr in March 2023 but fell to ₹578 Cr in September 2023. This inconsistency may reflect challenges in demand or operational efficiency. The company’s operating profit margin (OPM) has been relatively stable, averaging around 12% to 13% in recent quarters, although it dipped to 11% in the latest quarter. Such dynamics suggest that while Aarti Drugs has maintained a significant market presence, it faces headwinds in sustaining growth momentum amid a competitive landscape.
Profitability and Efficiency Metrics
The profitability of Aarti Drugs is underscored by its net profit of ₹190 Cr, translating to a return on equity (ROE) of 13.0% and a return on capital employed (ROCE) of 13.5%. These metrics align closely with industry standards, indicating effective management of capital. The interest coverage ratio (ICR) is robust at 8.46x, showcasing the company’s ability to meet interest obligations comfortably. Despite a reported operating profit of ₹286 Cr for the fiscal year ending March 2023, the profit margins have faced pressure, with net profit margins reported at 7.04% in the latest fiscal. The cash conversion cycle (CCC) of 127 days suggests a relatively efficient management of working capital, although it has increased from previous years, indicating potential delays in receivables or inventory turnover. Overall, while Aarti Drugs exhibits solid profitability, ongoing scrutiny of operational efficiency is essential to enhance margins further.
Balance Sheet Strength and Financial Ratios
Aarti Drugs maintains a balanced financial position, with total assets reported at ₹2,245 Cr and total liabilities at ₹2,273 Cr as of March 2025. The company’s borrowings amounted to ₹440 Cr, reflecting a manageable debt level, particularly with a long-term debt-to-equity ratio of 0.20, indicating low leverage. Reserves have steadily increased to ₹1,250 Cr, providing a cushion for future investments and operational resilience. The price-to-book value (P/BV) ratio stands at 2.27x, suggesting a moderate market valuation relative to the company’s book value. Additionally, the current ratio of 1.60 indicates sufficient liquidity to cover short-term obligations. However, the total debt-to-equity ratio of 0.44 raises a cautionary flag regarding financial leverage, which could impact the company in times of economic stress. Overall, Aarti Drugs exhibits financial stability, but maintaining a conservative approach to leverage will be crucial for future growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarti Drugs reveals a significant degree of promoter commitment, with promoters holding 54.72% of the shares. This level of ownership can instill investor confidence, as it often aligns the interests of management with those of shareholders. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 2.68% and 9.90% of the company, respectively, indicating moderate institutional interest. The public shareholding stands at 32.70%, with the number of shareholders recorded at 1,52,252 as of September 2025, reflecting a broad base of retail investors. However, a slight decline in promoter shareholding from 59.57% in March 2023 to the current level may raise concerns regarding insider confidence. Overall, while the ownership structure supports stability, fluctuations in promoter holdings could influence market perceptions and investor sentiment moving forward.
Outlook, Risks, and Final Insight
The outlook for Aarti Drugs must consider both the strengths and challenges identified in its operations. The company’s solid profitability metrics, strong balance sheet, and consistent cash flow position it well for future growth. However, risks include potential volatility in sales, evidenced by recent quarterly fluctuations, and the pressure on profit margins that may arise from increasing operational costs or competitive pricing strategies. Additionally, while the current debt levels are manageable, any economic downturn could necessitate a reevaluation of financial strategies. In scenarios where Aarti Drugs successfully navigates these risks—improving operational efficiency and maintaining sales growth—it could enhance its market position and profitability. Conversely, failure to address these challenges could lead to diminished investor confidence and a potential decline in market valuation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 121 Cr. | 96.2 | 195/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,521 Cr. | 323 | 479/192 | 72.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 71.3 Cr. | 48.7 | 49.3/17.0 | 170 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,593.21 Cr | 1,092.82 | 46.80 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 625 | 626 | 696 | 592 | 578 | 538 | 560 | 493 | 543 | 515 | 623 | 521 | 579 |
| Expenses | 555 | 557 | 608 | 520 | 512 | 478 | 490 | 439 | 484 | 454 | 534 | 457 | 504 |
| Operating Profit | 70 | 69 | 89 | 72 | 65 | 60 | 69 | 54 | 60 | 60 | 89 | 64 | 75 |
| OPM % | 11% | 11% | 13% | 12% | 11% | 11% | 12% | 11% | 11% | 12% | 14% | 12% | 13% |
| Other Income | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 11 | 2 | 0 | 0 |
| Interest | 8 | 9 | 8 | 8 | 8 | 7 | 8 | 7 | 7 | 8 | 7 | 7 | 6 |
| Depreciation | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 |
| Profit before tax | 50 | 49 | 69 | 53 | 47 | 43 | 50 | 35 | 41 | 52 | 71 | 45 | 56 |
| Tax % | 27% | 25% | 23% | 25% | 26% | 26% | 27% | 23% | 26% | 26% | 13% | -7% | 25% |
| Net Profit | 37 | 37 | 53 | 40 | 35 | 32 | 36 | 27 | 30 | 39 | 61 | 49 | 42 |
| EPS in Rs | 3.95 | 3.96 | 5.74 | 4.27 | 3.76 | 3.44 | 3.93 | 2.93 | 3.33 | 4.22 | 6.74 | 5.33 | 4.58 |
Last Updated: January 13, 2026, 7:16 am
Below is a detailed analysis of the quarterly data for Aarti Drugs Limited based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 579.00 Cr.. The value appears strong and on an upward trend. It has increased from 521.00 Cr. (Jun 2025) to 579.00 Cr., marking an increase of 58.00 Cr..
- For Expenses, as of Sep 2025, the value is 504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 457.00 Cr. (Jun 2025) to 504.00 Cr., marking an increase of 47.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 75.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Jun 2025) to 75.00 Cr., marking an increase of 11.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Jun 2025) to 13.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 6.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.00 Cr. (Jun 2025) to 6.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.00 Cr. (Jun 2025) to 14.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 56.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Jun 2025) to 56.00 Cr., marking an increase of 11.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from -7.00% (Jun 2025) to 25.00%, marking an increase of 32.00%.
- For Net Profit, as of Sep 2025, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Jun 2025) to 42.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.58. The value appears to be declining and may need further review. It has decreased from 5.33 (Jun 2025) to 4.58, marking a decrease of 0.75.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:43 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 972 | 1,087 | 1,076 | 1,089 | 1,140 | 1,454 | 1,635 | 1,915 | 2,251 | 2,498 | 2,267 | 2,174 | 2,237 |
| Expenses | 822 | 915 | 900 | 910 | 955 | 1,252 | 1,387 | 1,511 | 1,930 | 2,212 | 1,998 | 1,908 | 1,949 |
| Operating Profit | 150 | 172 | 176 | 179 | 185 | 203 | 248 | 404 | 321 | 286 | 269 | 265 | 288 |
| OPM % | 15% | 16% | 16% | 16% | 16% | 14% | 15% | 21% | 14% | 11% | 12% | 12% | 13% |
| Other Income | 1 | 1 | 0 | 4 | 1 | 6 | 9 | 7 | 5 | 2 | 4 | 14 | 14 |
| Interest | 37 | 42 | 47 | 38 | 36 | 41 | 36 | 26 | 23 | 36 | 33 | 32 | 28 |
| Depreciation | 28 | 31 | 36 | 37 | 38 | 40 | 47 | 48 | 47 | 47 | 48 | 48 | 50 |
| Profit before tax | 86 | 100 | 93 | 108 | 112 | 128 | 175 | 338 | 256 | 205 | 192 | 199 | 224 |
| Tax % | 28% | 22% | 29% | 30% | 35% | 32% | 22% | 24% | 24% | 25% | 26% | 21% | |
| Net Profit | 62 | 78 | 66 | 75 | 73 | 87 | 136 | 258 | 195 | 153 | 142 | 157 | 190 |
| EPS in Rs | 6.38 | 8.01 | 6.84 | 7.91 | 7.78 | 9.25 | 14.56 | 27.65 | 21.06 | 16.50 | 15.43 | 17.24 | 20.87 |
| Dividend Payout % | 26% | 41% | 25% | 3% | 3% | 3% | 3% | 9% | 5% | 6% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.81% | -15.38% | 13.64% | -2.67% | 19.18% | 56.32% | 89.71% | -24.42% | -21.54% | -7.19% | 10.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.19% | 29.02% | -16.30% | 21.84% | 37.14% | 33.38% | -114.12% | 2.88% | 14.35% | 17.75% |
Aarti Drugs Limited has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 4% |
| 3 Years: | -7% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -8% |
| 3 Years: | 3% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 18% |
| 3 Years: | 13% |
| Last Year: | 13% |
Last Updated: September 4, 2025, 10:00 pm
Balance Sheet
Last Updated: December 4, 2025, 12:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 | 91 |
| Reserves | 239 | 279 | 326 | 363 | 410 | 495 | 598 | 766 | 880 | 1,022 | 1,083 | 1,160 | 1,250 |
| Borrowings | 342 | 435 | 465 | 448 | 517 | 471 | 378 | 336 | 519 | 535 | 475 | 516 | 440 |
| Other Liabilities | 257 | 228 | 240 | 281 | 366 | 384 | 471 | 442 | 543 | 546 | 522 | 506 | 463 |
| Total Liabilities | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
| Fixed Assets | 373 | 431 | 463 | 542 | 564 | 586 | 612 | 631 | 649 | 634 | 722 | 761 | 970 |
| CWIP | 8 | 13 | 34 | 14 | 28 | 32 | 11 | 16 | 60 | 161 | 222 | 273 | 92 |
| Investments | 5 | 11 | 11 | 18 | 17 | 19 | 20 | 24 | 28 | 29 | 30 | 42 | 53 |
| Other Assets | 464 | 511 | 547 | 541 | 707 | 736 | 828 | 966 | 1,297 | 1,372 | 1,198 | 1,196 | 1,130 |
| Total Assets | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
Below is a detailed analysis of the balance sheet data for Aarti Drugs Limited based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,250.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,160.00 Cr. (Mar 2025) to 1,250.00 Cr., marking an increase of 90.00 Cr..
- For Borrowings, as of Sep 2025, the value is 440.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 516.00 Cr. (Mar 2025) to 440.00 Cr., marking a decrease of 76.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 463.00 Cr.. The value appears to be improving (decreasing). It has decreased from 506.00 Cr. (Mar 2025) to 463.00 Cr., marking a decrease of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 970.00 Cr.. The value appears strong and on an upward trend. It has increased from 761.00 Cr. (Mar 2025) to 970.00 Cr., marking an increase of 209.00 Cr..
- For CWIP, as of Sep 2025, the value is 92.00 Cr.. The value appears to be declining and may need further review. It has decreased from 273.00 Cr. (Mar 2025) to 92.00 Cr., marking a decrease of 181.00 Cr..
- For Investments, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 11.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,130.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,196.00 Cr. (Mar 2025) to 1,130.00 Cr., marking a decrease of 66.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
Notably, the Reserves (1,250.00 Cr.) exceed the Borrowings (440.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -192.00 | -263.00 | -289.00 | -269.00 | -332.00 | -268.00 | -130.00 | 68.00 | -198.00 | -249.00 | -206.00 | -251.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 103 | 109 | 93 | 117 | 110 | 104 | 96 | 115 | 117 | 104 | 118 |
| Inventory Days | 71 | 77 | 87 | 101 | 132 | 86 | 107 | 125 | 120 | 102 | 107 | 106 |
| Days Payable | 84 | 75 | 85 | 91 | 125 | 86 | 110 | 94 | 103 | 89 | 96 | 97 |
| Cash Conversion Cycle | 91 | 105 | 110 | 103 | 124 | 109 | 101 | 127 | 133 | 130 | 115 | 127 |
| Working Capital Days | -10 | 13 | 21 | 26 | 33 | 46 | 60 | 83 | 68 | 73 | 79 | 79 |
| ROCE % | 22% | 21% | 18% | 17% | 17% | 17% | 20% | 33% | 21% | 15% | 14% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 6,387,722 | 1.55 | 262.95 | 4,636,377 | 2025-12-07 00:37:57 | 37.77% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,721,924 | 1.1 | 70.88 | 1,453,383 | 2026-01-25 23:15:05 | 18.48% |
| DSP Healthcare Fund | 852,155 | 1.13 | 35.08 | 737,671 | 2025-12-07 01:59:04 | 15.52% |
| DSP Value Fund | 70,308 | 0.22 | 2.89 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Diluted EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Cash EPS (Rs.) | 24.53 | 24.26 | 23.40 | 27.54 | 35.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Revenue From Operations / Share (Rs.) | 261.54 | 275.04 | 293.31 | 268.75 | 231.20 |
| PBDIT / Share (Rs.) | 33.24 | 34.86 | 33.24 | 36.80 | 47.38 |
| PBIT / Share (Rs.) | 27.13 | 29.26 | 27.81 | 31.39 | 42.03 |
| PBT / Share (Rs.) | 23.20 | 25.62 | 24.21 | 29.15 | 39.59 |
| Net Profit / Share (Rs.) | 18.42 | 18.66 | 17.97 | 22.14 | 30.09 |
| NP After MI And SOA / Share (Rs.) | 18.42 | 18.65 | 17.96 | 22.14 | 30.09 |
| PBDIT Margin (%) | 12.71 | 12.67 | 11.33 | 13.69 | 20.49 |
| PBIT Margin (%) | 10.37 | 10.64 | 9.47 | 11.68 | 18.18 |
| PBT Margin (%) | 8.87 | 9.31 | 8.25 | 10.84 | 17.12 |
| Net Profit Margin (%) | 7.04 | 6.78 | 6.12 | 8.23 | 13.01 |
| NP After MI And SOA Margin (%) | 7.04 | 6.77 | 6.12 | 8.23 | 13.01 |
| Return on Networth / Equity (%) | 12.28 | 13.37 | 13.94 | 19.78 | 30.69 |
| Return on Capital Employeed (%) | 14.25 | 16.43 | 17.29 | 22.92 | 33.46 |
| Return On Assets (%) | 6.53 | 7.04 | 6.86 | 9.28 | 15.87 |
| Long Term Debt / Equity (X) | 0.20 | 0.21 | 0.17 | 0.13 | 0.16 |
| Total Debt / Equity (X) | 0.44 | 0.43 | 0.50 | 0.51 | 0.33 |
| Asset Turnover Ratio (%) | 0.95 | 1.04 | 1.17 | 1.18 | 1.19 |
| Current Ratio (X) | 1.60 | 1.66 | 1.60 | 1.48 | 1.77 |
| Quick Ratio (X) | 1.03 | 1.05 | 1.05 | 0.92 | 1.08 |
| Inventory Turnover Ratio (X) | 4.98 | 3.14 | 3.39 | 3.37 | 3.15 |
| Dividend Payout Ratio (NP) (%) | 5.42 | 5.36 | 5.56 | 4.51 | 8.30 |
| Dividend Payout Ratio (CP) (%) | 4.07 | 4.12 | 4.27 | 3.63 | 7.05 |
| Earning Retention Ratio (%) | 94.58 | 94.64 | 94.44 | 95.49 | 91.70 |
| Cash Earning Retention Ratio (%) | 95.93 | 95.88 | 95.73 | 96.37 | 92.95 |
| Interest Coverage Ratio (X) | 8.46 | 9.56 | 9.25 | 16.42 | 19.24 |
| Interest Coverage Ratio (Post Tax) (X) | 5.69 | 6.12 | 6.00 | 10.88 | 13.20 |
| Enterprise Value (Cr.) | 3706.38 | 4541.99 | 3725.82 | 4488.49 | 6770.51 |
| EV / Net Operating Revenue (X) | 1.55 | 1.80 | 1.37 | 1.80 | 3.14 |
| EV / EBITDA (X) | 12.22 | 14.17 | 12.10 | 13.17 | 15.33 |
| MarketCap / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| Retention Ratios (%) | 94.57 | 94.63 | 94.43 | 95.48 | 91.69 |
| Price / BV (X) | 2.27 | 3.11 | 2.62 | 3.83 | 7.09 |
| Price / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| EarningsYield | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 |
After reviewing the key financial ratios for Aarti Drugs Limited, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.53. This value is within the healthy range. It has increased from 24.26 (Mar 24) to 24.53, marking an increase of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 261.54. It has decreased from 275.04 (Mar 24) to 261.54, marking a decrease of 13.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 33.24. This value is within the healthy range. It has decreased from 34.86 (Mar 24) to 33.24, marking a decrease of 1.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 27.13. This value is within the healthy range. It has decreased from 29.26 (Mar 24) to 27.13, marking a decrease of 2.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.20. This value is within the healthy range. It has decreased from 25.62 (Mar 24) to 23.20, marking a decrease of 2.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.66 (Mar 24) to 18.42, marking a decrease of 0.24.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.65 (Mar 24) to 18.42, marking a decrease of 0.23.
- For PBDIT Margin (%), as of Mar 25, the value is 12.71. This value is within the healthy range. It has increased from 12.67 (Mar 24) to 12.71, marking an increase of 0.04.
- For PBIT Margin (%), as of Mar 25, the value is 10.37. This value is within the healthy range. It has decreased from 10.64 (Mar 24) to 10.37, marking a decrease of 0.27.
- For PBT Margin (%), as of Mar 25, the value is 8.87. This value is below the healthy minimum of 10. It has decreased from 9.31 (Mar 24) to 8.87, marking a decrease of 0.44.
- For Net Profit Margin (%), as of Mar 25, the value is 7.04. This value is within the healthy range. It has increased from 6.78 (Mar 24) to 7.04, marking an increase of 0.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.04. This value is below the healthy minimum of 8. It has increased from 6.77 (Mar 24) to 7.04, marking an increase of 0.27.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.28. This value is below the healthy minimum of 15. It has decreased from 13.37 (Mar 24) to 12.28, marking a decrease of 1.09.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.25. This value is within the healthy range. It has decreased from 16.43 (Mar 24) to 14.25, marking a decrease of 2.18.
- For Return On Assets (%), as of Mar 25, the value is 6.53. This value is within the healthy range. It has decreased from 7.04 (Mar 24) to 6.53, marking a decrease of 0.51.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.20, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 0.44, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.95. It has decreased from 1.04 (Mar 24) to 0.95, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.60. This value is within the healthy range. It has decreased from 1.66 (Mar 24) to 1.60, marking a decrease of 0.06.
- For Quick Ratio (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 1.05 (Mar 24) to 1.03, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.98. This value is within the healthy range. It has increased from 3.14 (Mar 24) to 4.98, marking an increase of 1.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.42. This value is below the healthy minimum of 20. It has increased from 5.36 (Mar 24) to 5.42, marking an increase of 0.06.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.07. This value is below the healthy minimum of 20. It has decreased from 4.12 (Mar 24) to 4.07, marking a decrease of 0.05.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.58. This value exceeds the healthy maximum of 70. It has decreased from 94.64 (Mar 24) to 94.58, marking a decrease of 0.06.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.93. This value exceeds the healthy maximum of 70. It has increased from 95.88 (Mar 24) to 95.93, marking an increase of 0.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 9.56 (Mar 24) to 8.46, marking a decrease of 1.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.69. This value is within the healthy range. It has decreased from 6.12 (Mar 24) to 5.69, marking a decrease of 0.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,706.38. It has decreased from 4,541.99 (Mar 24) to 3,706.38, marking a decrease of 835.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has decreased from 1.80 (Mar 24) to 1.55, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 12.22. This value is within the healthy range. It has decreased from 14.17 (Mar 24) to 12.22, marking a decrease of 1.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 94.57. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.57, marking a decrease of 0.06.
- For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 3.11 (Mar 24) to 2.27, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Drugs Limited:
- Net Profit Margin: 7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.25% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.28% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.03
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.3 (Industry average Stock P/E: 46.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 198, M.I.D.C., Palghar District Maharashtra 401506 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant V Gogri | Chairman Emeritus |
| Mr. Prakash M Patil | Chairman & M.D & CEO |
| Mr. Rashesh C Gogri | Managing Director |
| Mr. Harshit M Savla | Joint Managing Director |
| Mr. Harit P Shah | Executive Director |
| Mr. Uday M Patil | Executive Director |
| Mr. Narendra J Salvi | Non Executive Director |
| Mr. Ankit V Paleja | Independent Director |
| Prof. Bhaskar N Thorat | Independent Director |
| Mrs. Neha R Gada | Independent Director |
| Mr. Hasmukh B Dedhia | Independent Director |
| Mr. Sandeep M Joshi | Independent Director |
| Mr. Ajit E Venugopalan | Independent Director |
FAQ
What is the intrinsic value of Aarti Drugs Limited?
Aarti Drugs Limited's intrinsic value (as of 01 February 2026) is ₹279.99 which is 26.51% lower the current market price of ₹381.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,478 Cr. market cap, FY2025-2026 high/low of ₹575/312, reserves of ₹1,250 Cr, and liabilities of ₹2,245 Cr.
What is the Market Cap of Aarti Drugs Limited?
The Market Cap of Aarti Drugs Limited is 3,478 Cr..
What is the current Stock Price of Aarti Drugs Limited as on 01 February 2026?
The current stock price of Aarti Drugs Limited as on 01 February 2026 is ₹381.
What is the High / Low of Aarti Drugs Limited stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Drugs Limited stocks is ₹575/312.
What is the Stock P/E of Aarti Drugs Limited?
The Stock P/E of Aarti Drugs Limited is 18.3.
What is the Book Value of Aarti Drugs Limited?
The Book Value of Aarti Drugs Limited is 147.
What is the Dividend Yield of Aarti Drugs Limited?
The Dividend Yield of Aarti Drugs Limited is 0.26 %.
What is the ROCE of Aarti Drugs Limited?
The ROCE of Aarti Drugs Limited is 13.5 %.
What is the ROE of Aarti Drugs Limited?
The ROE of Aarti Drugs Limited is 13.0 %.
What is the Face Value of Aarti Drugs Limited?
The Face Value of Aarti Drugs Limited is 10.0.